BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...code for this constellation of pathologies, which encompass...
BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

Near the end of a year when most of Gilead’s over $30 billion in deals were in cancer, the company’s latest billion-dollar acquisition showed an appetite for growth in its area of greatest historical strength:...
BioCentury | Nov 26, 2020
Finance

Pre-profit biotechs on Hong Kong exchange, STAR board could see investment influx via Stock Connect expansion

Pre-profit biotechs listed on the Hong Kong stock exchange or Shanghai’s STAR board could soon see an influx of investment as the Chinese government expands the Stock Connect channel linking financial...
BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

Pfizer’s Rod MacKenzie says the collaborations and accelerated timelines taking place during COVID-19 are causing introspection in pharmas for how they operate, and for how they can push for regulators...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Sep 7, 2020
Product Development

Covert disease surveillance capacity needed to detect future pandemics, says Gottlieb: a BioCentury audio interview

...they could bring online quickly” (see “Pandemic Preparedness”).He said the strategic build-up of countermeasures should encompass...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Exon skipping therapy for Batten disease

DISEASE CATEGORY: Neurology INDICATION: Neurology Antisense oligonucleotides that induce exon skipping in lysosomal membrane protein CLN3 could treat CLN3 Batten disease, a neurodegenerative lysosomal...
BioCentury | Aug 11, 2020
Product Development

BIOEquality, data sharing and deals: a BioCentury podcast

...also in that top five and those encompass...
BioCentury | Jul 31, 2020
Product Development

Can the vogue of decentralized trials continue beyond the pandemic?

...long been attractive for its ability to reduce dependence on major academic medical centers and encompass...
BioCentury | Jul 8, 2020
Deals

Chromatin remodeling gains traction with Merck-Foghorn partnership

Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction. Under the deal, Merck & Co. Inc. (NYSE:MRK) will have exclusive, global rights to cancer therapies targeting dysregulation of an...
Items per page:
1 - 10 of 241
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...code for this constellation of pathologies, which encompass...
BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

Near the end of a year when most of Gilead’s over $30 billion in deals were in cancer, the company’s latest billion-dollar acquisition showed an appetite for growth in its area of greatest historical strength:...
BioCentury | Nov 26, 2020
Finance

Pre-profit biotechs on Hong Kong exchange, STAR board could see investment influx via Stock Connect expansion

Pre-profit biotechs listed on the Hong Kong stock exchange or Shanghai’s STAR board could soon see an influx of investment as the Chinese government expands the Stock Connect channel linking financial...
BioCentury | Sep 11, 2020
Product Development

Pfizer’s MacKenzie: Other diseases deserve the same acceleration as COVID-19: a BioCentury audio interview

Pfizer’s Rod MacKenzie says the collaborations and accelerated timelines taking place during COVID-19 are causing introspection in pharmas for how they operate, and for how they can push for regulators...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development. ...
BioCentury | Sep 7, 2020
Product Development

Covert disease surveillance capacity needed to detect future pandemics, says Gottlieb: a BioCentury audio interview

...they could bring online quickly” (see “Pandemic Preparedness”).He said the strategic build-up of countermeasures should encompass...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Exon skipping therapy for Batten disease

DISEASE CATEGORY: Neurology INDICATION: Neurology Antisense oligonucleotides that induce exon skipping in lysosomal membrane protein CLN3 could treat CLN3 Batten disease, a neurodegenerative lysosomal...
BioCentury | Aug 11, 2020
Product Development

BIOEquality, data sharing and deals: a BioCentury podcast

...also in that top five and those encompass...
BioCentury | Jul 31, 2020
Product Development

Can the vogue of decentralized trials continue beyond the pandemic?

...long been attractive for its ability to reduce dependence on major academic medical centers and encompass...
BioCentury | Jul 8, 2020
Deals

Chromatin remodeling gains traction with Merck-Foghorn partnership

Merck’s Wednesday deal with Foghorn is the latest signal that chromatin remodeling is gaining traction. Under the deal, Merck & Co. Inc. (NYSE:MRK) will have exclusive, global rights to cancer therapies targeting dysregulation of an...
Items per page:
1 - 10 of 241